Lung Cancer
Conference Coverage
Larotrectinib responses support routine NTRK gene fusion testing for lung cancer
GENEVA – Although NTRK fusions are relatively infrequent in lung cancer, a subgroup analysis demonstrates an overall...
Conference Coverage
Pooled KEYNOTE data support pembro for elderly patients with NSCLC
GENEVA – Investigators analyzed data from 264 patients 75 years or older involved in the KEYNOTE-010, KEYNOTE-024,...
Conference Coverage
Tumor-treating fields boost chemo for mesothelioma
GENEVA - Patients with malignant pleural mesothelioma who were treated with TTFields in combination with pemetrexed and...
News
FDA approves pembrolizumab for first-line stage III NSCLC
Approval was based on improved overall survival for patients taking pembrolizumab, compared with those taking the investigators’ choice of...
Conference Coverage
European NAVIGATE data support safety of electromagnetic navigation bronchoscopy
GENEVA – For lung lesion biopsy, electromagnetic navigation bronchoscopy offers high navigational success with a relatively low rate of...
Conference Coverage
MET/MEK inhibitor duo shows activity in resistant NSCLC
ATLANTA – About one-third of patients with heavily pretreated non–small cell lung cancer had responses to osimertinib and selumetinib.
Conference Coverage
Anti-EGFR TKI, MET inhibitor team up against drug-resistant NSCLC
ATLANTA – Dr. Lecia Sequist discusses early results from the TATTON trial, which is evaluating osimertinib plus...
Conference Coverage
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of...
From the Journals
Caring for aging HIV-infected patients requires close attention to unrelated diseases
Feature
Lifetime cost of tobacco use tops $1.9 million per smoker
Connecticut’s estimated cost is more than twice as high as Georgia’s.